Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,156 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acquired Immunodeficiency Syndrome Clear all

Conditions: Alcohol Use Disorder (AUD), HIV
Interventions: semaglutide; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: HIV Infection, Substance Abuse
Interventions: empowerment theory-based small group discussion, individual resilience counseling; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Miami Beach, Florida • Wilton Manors, Florida

Conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
Interventions: Cognitive Rehabilitation; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV
Interventions: School Support Intervention; Behavioral
Lead sponsor: Pacific Institute for Research and Evaluation; Other
Eligibility: Not listed
Enrollment: 835 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Telinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Diego, California • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: HIV Infection, Advanced End Stage Heart Failure
Interventions: HIV-positive heart transplant; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more

Conditions: HIV Infections
Interventions: Thiamine hydrochloride, Riboflavin, Ascorbic acid, Vitamin E; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Denver, Colorado • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: HIV-1-infection, Medication Adherence, Satisfaction, Patient
Interventions: Home visit delivery strategy; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: HIV Infections
Interventions: PGT121, PGDM1400, 10-1074, VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: HIV Infections
Interventions: Treatment regimen change; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 23
States / cities: Menlo Park, California • Stanford, California • Torrance, California + 15 more

Conditions: HIV Infections
Interventions: TPV oral solution, RTV oral solution; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 9
States / cities: Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Antiretroviral Therapy (ART) Adherence, Health Behavior
Interventions: LifeWindows Intervention Sessions, Control; Behavioral · Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Farmington, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 1 more

Conditions: Hiv
Interventions: Preventing AIDS Through Live Movement and Sound (PALMS); Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years to 18 Years · Male only
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Blood plasma collection, Cervical and Vaginal Biopsy, Colonoscopy with Ileal and Rectal Biopsy; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea, Syphilis, Trichomonas
Interventions: Mobile Van Clinic; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute HIV Infection, HIV Infections
Interventions: efavirenz, emtricitabine, and tenofovir; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections, Drug Abuse
Interventions: Disulfiram, Disulfiram + Efavirenz, Disulfiram + Atazanavir, Disulfiram + Ritonavir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Search by objective public record fields.

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)

HIV Medication Adherence in Underserved Populations

School Support as Structural HIV Prevention for Adolescent Orphans in Kenya

A Phase I Randomized Dose/Formulation Comparison Study of SC-52151

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs

Implementing Cabenuva in Arkansas HIV Programs

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC

Improving Treatment Adherence in HIV-Infected Individuals

Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents

Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects

Rapid HIV Tests for Women Late in Pregnancy and During Labor

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Disulfiram Interactions With HIV Medications: Clinical Implications

Optimizing Kidney Transplant Informed Consent